MTMariana Bertoncelli Tanaka

Mariana Bertoncelli Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariana Bertoncelli Tanaka has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy ( IB1 ‐ LaserComplete study)

    by Martin J. Connor, Archana Gopalakrishnan, Nikhil Mayor, Eva Bolton, Sami Hamid, Sai Kalpitha Reddy, Tayla Perreau, Eslam Maher, Alexander Light, Samuel Morris, et al.

    Objectives: To evaluate ex vivo fluorescence confocal microscopy (FCM) for immediate detrusor muscle (DM) assessment during primary transurethral resection of bladder tumour (TURBT). Patients and Methods: This prospective, blinded, paired‐cohort feasibility study enrolled consecutive patients undergoing primary TURBT for suspected non‐muscle‐invasive bladder cancer between September 2024 and September 2025 (IB1‐LaserComplete study; International Standard Randomised Controlled Trial Number Register [ISRCTN]16114765). Ex vivo FCM generates immediate high‐resolution digital images of fresh tissue, enabling immediate DM assessment. Intraoperative ex vivo FCM imaging of en face tumour base specimens was performed using the Histolog® scanner (SamanTree Medical SA, Lausanne, Switzerland). DM status was reported by a blinded uro‐pathologist and urologist. Formalin‐fixed histopathology served as the reference standard. The primary outcome was technical feasibility, defined as acquisition of an interpretable FCM image. Secondary outcomes included exploratory diagnostic performance, inter‐observer agreement and time to confirmation of DM status. Results: A total of 34 patients were recruited and 30 had evaluable paired specimens. DM was absent in 13% (four of 30). FCM was sufficient for determining DM status in all patients (100%; 30 of 30). Sensitivity, specificity, positive predictive value, negative predictive value (NPV) were 42% (95% confidence interval [CI] 26–61%), 100% (95% CI 51–100%), 100% (95% CI 74–100%), and 21% (95% CI 9–43%), respectively. Inter‐observer agreement between the uro‐pathologist and urologist was high at 83% (κ = 0.72, 95% CI 0.47–0.97). The median (interquartile range) time to confirm DM status was 5.4 (4.95–5.39) min vs 11 (7–13.8) days using standard histopathology. Conclusion: Fluorescence confocal microscopy is feasible for rapid intraoperative imaging of TURBT specimens and demonstrates excellent specificity for detection of DM. However, its low sensitivity and NPV preclude use as a stand‐alone tool to exclude DM intraoperatively. Based on these findings, FCM should not guide intraoperative decision making outside research settings.


  • Open Access

    Deep learning for fluorescence confocal microscopy image interpretation in radical prostatectomy

    by Lixiang Fang, Nikhil Mayor, Alexander Light, Anna Silvanto, Aiman Haider, Chase Ng, Archana Gopalakrishnan, Ranil Johann Boaz, Mariana Bertoncelli Tanaka, Bijan Khoubehi, et al.

    Objective: To develop and validate a deep learning model for interpretation of fluorescence confocal microscopy (FCM) images for intraoperative surgical margin assessment during radical prostatectomy (RP). Patients and Methods: Fluorescence confocal microscopy images from the multicentre Imperial Prostate 8‐Fluorescence Confocal Microscopy for Rapid Evaluation of Surgical Cancer Excision (IP8‐FLUORESCE) study were used to train and test a convolutional neural network model. The modified model incorporated focal loss with label smoothing, dropout regularisation, adaptive class weighting, and weighted sampling to address pronounced class imbalance. Images were pre‐processed by extracting regions of interest at a defined digital zoom level and normalised to 896 × 896 pixels. The reference standard was surgical margin status on conventional histopathology assessed by an expert histopathologist. Diagnostic performance was assessed using sensitivity, specificity, positive and negative predictive value, area under the receiver‐operating‐characteristic curve (AUC), and calibration via Brier scores. External validation was conducted using an independent dataset from the LaserSAFE feasibility trial. Model explainability was evaluated using Gradient‐weighted Class Activation Mapping (Grad‐CAM) and a custom graphical user interface (GUI) was developed to support real‐time deployment. Results: A total of 275 images (37 tumour and 238 benign from 24 patients) were included for model development and internal testing. On the internal test set ( n = 57), the model achieved a sensitivity of 87.5%, specificity of 97.9%, and an AUC of 0.93, with good calibration (Brier score 0.16). External validation using 46 independent images yielded a sensitivity of 91.3%, specificity of 73.9%, and an AUC of 0.83, with acceptable calibration (Brier score 0.20). Grad‐CAM visualisations aligned with malignant structures on FCM images, and the GUI enabled rapid, interpretable predictions in <2 s. Conclusions: We developed and validated a deep learning model for interpretation of FCM images from RP specimens, which demonstrated strong discriminative performance and generalisability for automated FCM interpretation. This approach represents a scalable solution for real‐time intraoperative margin assessment and may reduce reliance on intraoperative pathology support.


  • Open Access

    Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis

    by Deepika Reddy, Marieke van Son, Max Peters, Mariana Bertoncelli Tanaka, Tim Dudderidge, Emma Cullen, Carmen Lok Tung Ho, Richard G. Hindley, Amr Emara, Stuart McCracken, et al.

    Focal therapy treats individual areas of tumour in non-metastatic prostate cancer in patients unsuitable for active surveillance. The aim of this work was to evaluate the cost-effectiveness of focal therapy versus prostatectomy and external beam radiotherapy (EBRT). A Markov cohort health state transition model with four health states (stable disease, local recurrence, metastatic disease and death) was created, evaluating costs and utilities over a 10-year time horizon for patients diagnosed with non-metastatic prostate cancer. National Health Service (NHS) for England perspective was used, based on direct healthcare costs. Clinical transition probabilities were derived from prostate cancer registries in patients undergoing radical prostatectomy, EBRT and focal therapy using cryotherapy (Boston Scientific) or high-intensity focused ultrasound (HIFU) (Sonablate). Propensity score matching was used to ensure at-risk populations were comparable. Variables included age, prostate-specific antigen (PSA), International Society of Urological Pathology (ISUP) grade group, maximum cancer core length (mm), T-stage and year of treatment. Focal therapy was associated with a lower overall cost and higher quality adjusted life year (QALY) gains than either prostatectomy or EBRT, dominating both treatment strategies. Positive incremental net monetary benefit (NMB) values confirm focal therapy as cost effective versus the alternatives at a willingness to pay (WTP) threshold of £30,000/QALY. One-way deterministic sensitivity analyses revealed consistent results. Data used to calculate the transition probabilities were derived from a limited number of hospitals meaning that other potential treatment options were excluded. Limited data were available on later outcomes and none on quality of life data, therefore, literature-based estimates were used. Cost-effectiveness modelling demonstrates use of focal therapy (cryotherapy or HIFU) is associated with greater QALY gains at a lower overall cost than either radical prostatectomy or EBRT, representing good value for money in the NHS.


  • Open Access

    The rapid assessment for prostate imaging and diagnosis ( RAPID ) prostate cancer diagnostic pathway

    by David Eldred‐Evans, Martin J. Connor, Mariana Bertoncelli Tanaka, Edward Bass, Deepika Reddy, Uma Walters, Luke Stroman, Easter Espinosa, Raj Das, Nalin Khosla, et al.

    Objective: To report outcomes within the Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) diagnostic pathway, introduced to reduce patient and healthcare burdens and standardize delivery of pre‐biopsy multiparametric magnetic resonance imaging (MRI) and transperineal biopsy. Patients and Methods: A total of 2130 patients from three centres who completed the RAPID pathway (3 April 2017 to 31 March 2020) were consecutively entered as a prospective registry. These patients were also compared to a pre‐RAPID cohort of 2435 patients. Patients on the RAPID pathway with an MRI score 4 or 5 and those with PSA density ≥0.12 and an MRI score 3 were advised to undergo a biopsy. Primary outcomes were rates of biopsy and cancer detection. Secondary outcomes included comparison of transperineal biopsy techniques, patient acceptability and changes in time to diagnosis before and after the introduction of RAPID. Results: The median patient age and PSA level were 66 years and 6.6 ng/mL, respectively. Biopsy could be omitted in 43% of patients (920/2130). A further 7.9% of patients (168/2130) declined a recommendation for biopsy. The percentage of biopsies avoided among sites varied (45% vs 36% vs 51%; P < 0.001). In all, 30% (221/742) had a local anaesthetic (grid and stepper) transperineal biopsy. Clinically significant cancer detection (any Gleason score ≥3 + 4) was 26% (560/2130) and detection of Gleason score 3 + 3 alone constituted 5.8% (124/2130); detection of Gleason score 3 + 3 did not significantly vary among sites ( P = 0.7). Among participants who received a transperineal targeted biopsy, there was no difference in cancer detection rates among local anaesthetic, sedation and general anaesthetic groups. In the 2435 patients from the pre‐RAPID cohor, time to diagnosis was 32.1 days (95% confidence interval [CI] 29.3–34.9) compared to 15.9 days (95% CI 12.9–34.9) in the RAPID group. A total of 141 consecutive patient satisfaction surveys indicated a high satisfaction rate with the pathway; 50% indicated a preference for having all tests on a single day. Conclusions: The RAPID prostate cancer diagnostic pathway allows 43% of men to avoid a biopsy while preserving good detection of clinically significant cancers and low detection of insignificant cancers, although there were some centre‐level variations.


  • Assessing the regional variability of a pre-biopsy mpMRI and targeted prostate cancer diagnostic pathway

    by D.T. Reddy, D. Eldred-Evans, M. Connor, F. Hosking-Jervis, M. Bertoncelli Tanaka, H. Bhola-Stewart, W. Maynard, C. Khoo, T. Shah, E. Bass, et al.

  • PD-0416 Derivation and external validation of a RAPID Risk score for predicting significant prostate cancer

    by M. Peters, D. Eldred-Evans, M.J. Connor, M. Bertoncelli Tanaka, H. Bhola-Stewart, T. T Shah, S. Ahmad, M. Noureldin, K. Wong, H. Tam, et al.

  • Open Access

    1346 A retrospective, five-year review of presentation, investigations and management of acute testicular pain in paediatric patients

    by Alexandra Mundell, William Maynard, Nimlan Shanmugathas, Mariana Bertoncelli Tanaka, Tom Orton, James Patrick, Suks Minhas

    Background Testicular torsion (TT) is a urological emergency that must be considered in patients with acute testicular pain (ATP). The literature is conflicted on both distinguishing features in presentation of TT, compared to other causes of ATP, and the use of investigations in diagnosis (1). Testicular salvage rates are known to be improved by surgical detorsion of testis within 4–8 hours of symptom onset (2). Follow-up after scrotal exploration allows assessment of fertility and hormone production secondary to testicular atrophy (1). (1) DaJusta DG, Granberg CF, Villanueva C, Baker LA. Contemporary review of testicular torsion: new concepts, emerging technologies and potential therapeutics. J Pediatr Urol. 2013;9(6 Pt A):723–730. doi:10.1016/j.jpurol.2012.08.012 (2) Sharp VJ, Kieran K, Arlen AM. Testicular torsion: diagnosis, evaluation, and management. Am Fam Physician. 2013;88(12):835–840. Objectives To investigate ATP, in particular TT, regarding presentation, investigations and management in paediatric patients. Methods A retrospective review of paediatric patients who presented with ATP who underwent scrotal exploration between June 2015 and March 2020. Patients with a history of trauma were excluded. Results 81 patients, aged 5–18 years (median age 12), underwent exploration; 29% had TT, 21% epidydimo-orchitis (EO), 29% torted hyatid (TH), 12% normal testes, 4% intermittent torsion and 4% other diagnosis. In age groups up to 12 years, EO and TA were the most common diagnosis. EO also accounted for 57% of ATP in the 17–18 years old age group. TT caused ATP in 53% of cases in ages 13–14 years and 69% in ages 15–16 years. Patients who presented with nausea and vomiting were 2.7- and 2.5-fold more likely to be diagnosed with TT, respectively. An abnormal lie of testis was 3-fold more common in patients with TT. 30% of TT patients presented with an intact cremasteric reflex. Of those that presented within 4 hours, the most common diagnosis for ATP was TT (44%). Causes for ATP were more evenly distributed amongst different diagnoses after 4 hours. Urine analysis and ultrasonography were used in 59% and 18% of cases, respectively. Urine analysis was not sensitive or specific for TT. Ultrasound never falsely diagnosed TT in 15% of patients. The orchidectomy rate was 32% and all patients who required orchidectomy presented with symptoms lasting 12 hours or more, with one patient who presented after 12 hours of symptoms having viable testicular tissue. 32% of patients were offered follow-up following scrotal exploration and 14% underwent post-surgery ultrasound. Conclusions Patients, aged 13–16 years old, who present with ATP within 4 hours after symptom onset, associated nausea, vomiting and abnormal lie of testes, are highly likely to have TT. Urine analysis and ultrasonography were not widely used in our studied centres. The orchidectomy rate in this study is in line with others in the literature. Orchidectomy was only required in patients presenting after 12 hours of symptoms. Viable testicular tissue revealed in histology provides a warning of caution to surgeons when considering orchidectomy. Follow-up post-exploration was not routinely performed.


  • Prostate cancer in transgender women: what does a urologist need to know?

    by Mariana Bertoncelli Tanaka, Kirpal Sahota, James Burn, Alison Falconer, Mathias Winkler, Hashim U. Ahmed, Tina G. Rashid, the Gender Research Collaborative

    Objective: To review of the existing literature, current guidelines and standard of practice related to prostate cancer in transgender women, as the transgender population share many of the same healthcare needs as their cisgender counterparts, but may have additional specialist needs. Materials and methods: We performed a non‐systematic review of the literature, current guidelines and standard of practice related to prostate cancer in transgender women. Results: Our search revealed 10 case reports of prostate cancer in transgender women, four specialist opinion papers, six cohort studies, and four systematic reviews. The information in these publications were assimilated to produce a review of prostate cancer in transgender women. Conclusion: The risk of prostate cancer in transgender women who are not on gender‐affirming hormone therapy (GAHT) or who have not had gender‐affirming surgery (GAS) and gender non‐conforming individuals (who may never commence GAHT or have GAS) is the same as that in the cis male population. In these patients, healthcare professionals need to be able to discuss screening, diagnostic and treatment options considering future wishes for gender‐affirming treatment. Prostate cancer incidence in transgender women on GAHT or following GAS is lower than age‐matched cis‐male counterparts, but diagnosis and treatment is more nuanced. The present review discusses the existing literature about development and incidence of prostate cancer in this population, and makes recommendations about screening, the usefulness of diagnostic tools e.g. prostate‐specific antigen and magnetic resonance imaging, and considerations when formulating treatment. Potential directions for future research are discussed, which will hopefully lead to development of robust evidence‐based guidelines for the diagnosis and management of prostate cancer in transgender women.


  • Open Access

    Safety and adverse events of urgent elective surgery during COVID-19 within three UK hospitals

    by M Bertoncelli Tanaka, E R St John, G Exarchos, K Hogben, H U Ahmed, D Hrouda, J Patrick, A Mundell, G Scrimgeour, H Abboudi, et al.

    Dear Editor


  • Paternal age and assisted reproductive technology: problem solver or trouble maker?

    by Mariana Bertoncelli Tanaka, Ashok Agarwal, Sandro C. Esteves

    In our society, the number of couples with advanced reproductive age seeking fertility treatment is increasing steadily. While the negative effect of female age on assisted reproductive technology (ART) outcomes is well established, the impact of paternal age needs to be clarified. We reviewed the current literature to determine whether advanced paternal age affects the results of ART and the health of resulting offspring. We found that the published literature is overall supportive of a positive association between advanced paternal age (>40 years) and semen quality deterioration. However, the existing evidence does not corroborate nor discard the influence of advanced paternal age on ART outcomes. Similarly, the effect of paternal age on the health of ART offspring remains equivocal, although data from naturally-conceived children clearly indicates that advanced paternal age increases the frequency of genetic, neurodevelopmental, and psychiatric diseases in the progeny. Noteworthy, the current literature is limited and subjected to bias due to the impact of maternal age as a critical confounder. Health care providers should discuss with concerned couples the available options to counteract the possible negative influence of advanced paternal age on ART outcomes and health of resulting offspring. These include identification and treatment of underlying conditions with potential negative long-term effects on fertility, sperm freezing at a young age, and use of antioxidant supplements for men at risk of excessive oxidative stress. Aged male partner from couples undergoing ART, in particular men of 50 years and older, should consider use of preimplantation genetic testing as a means to detect embryo abnormalities and select euploid embryos for transfer to the uterine cavity.